Characterising the Increasing Prevalence of Crystal Methamphetamine Use in Vancouver, Canada, from 2006-2017: A Gender-based Analysis

Overview

Journal Drug Alcohol Rev

Specialty Psychiatry

Date 2020 Jul 16

PMID 32666650

Citations 25

Authors

Paxton Bach

Kanna Hayashi

M-J Milloy

Ekaterina Nosova

Thomas Kerr

Evan Wood

Nadia Fairbairn

Affiliations

Soon will be listed here.

Abstract

Introduction: Methamphetamine use is increasing in North America and is associated with numerous negative health effects and social harms. As drug-related harms are often gendered, this study sought to examine the differential impacts of gender on the trends, risk factors and health implications of crystal methamphetamine use among a Canadian cohort of people with high rates of injection polysubstance use.

Methods: Data were collected from two prospective cohorts of people who inject drugs in Vancouver, Canada. We examined trends in reported crystal methamphetamine use from 2006-2017 using the Cochrane-Armitage test for trend. We used multivariable generalised estimating equations, stratified by gender, to determine independent risk factors and health outcomes associated with crystal methamphetamine use.

Results: In total, 1984 participants were included in the study, including 694 (35%) women. The prevalence of reported crystal methamphetamine use within the previous 6 months rose from 19% in 2006 to 36% in 2017, with a rise seen in both genders (P < 0.001). Reported crystal methamphetamine use was associated with numerous risk behaviours and drug-related harms in both genders, and in women it was associated with an increase in experiences of sexual violence (adjusted odds ratio 1.64, 95% confidence interval 1.18, 2.27).

Conclusions: These findings demonstrate the rising prevalence of reported crystal methamphetamine use in Vancouver in a cohort with high rates of polysubstance use. This work highlights drug and sex-related risk behaviours associated with crystal methamphetamine use for both genders, and underscores the need to develop strategies to address the growing use of crystal methamphetamine.

Citing Articles

Chronic disease diagnoses and health service use among people who died of illicit drug toxicity in British Columbia, Canada.

Palis H, Hu K, Tu A, Scheuermeyer F, Staples J, Moe J BMC Med. 2024; 22(1):479.

PMID: 39593053 PMC: 11600560. DOI: 10.1186/s12916-024-03646-y.

Perspectives of key interest groups regarding supervised Consumption sites (SCS) and novel virtual harm reduction services / overdose response hotlines and applications: a qualitative Canadian study.

Seo B, Rioux W, Teare A, Rider N, Jones S, Taplay P Harm Reduct J. 2024; 21(1):141.

PMID: 39068494 PMC: 11282589. DOI: 10.1186/s12954-024-01053-3.

Model-based and model-free mechanisms in methamphetamine use disorder.

Robinson A, Mahlberg J, Chong T, Verdejo-Garcia A Addict Biol. 2024; 29(1):e13356.

PMID: 38221809 PMC: 10898847. DOI: 10.1111/adb.13356.

Epidemiology of acute infections in people who inject drugs in Australia.

Attwood L, OKeefe D, Higgs P, Vujovic O, Doyle J, Stewardson A Drug Alcohol Rev. 2023; 43(1):304-314.

PMID: 37995135 PMC: 10952783. DOI: 10.1111/dar.13772.

Cannabis use to manage stimulant cravings among people who use unregulated drugs.

Reddon H, Socias M, DeBeck K, Hayashi K, Walsh Z, Milloy M Addict Behav. 2023; 148:107867.

PMID: 37748225 PMC: 10896268. DOI: 10.1016/j.addbeh.2023.107867.

References

Hayashi H, Patterson T, Semple S, Fujimoto K, Stockman J . Risk Factors for Recent Intimate Partner Violence among Methamphetamine-Using Men and Women. J Psychoactive Drugs. 2016; 48(2):135-45. PMC: 4882313. DOI: 10.1080/02791072.2016.1170249. View

Hser Y, Evans E, Huang Y . Treatment outcomes among women and men methamphetamine abusers in California. J Subst Abuse Treat. 2005; 28(1):77-85. DOI: 10.1016/j.jsat.2004.10.009. View

Darke S . Self-report among injecting drug users: a review. Drug Alcohol Depend. 1998; 51(3):253-63; discussion 267-8. DOI: 10.1016/s0376-8716(98)00028-3. View

Iversen J, Page K, Madden A, Maher L . HIV, HCV, and Health-Related Harms Among Women Who Inject Drugs: Implications for Prevention and Treatment. J Acquir Immune Defic Syndr. 2015; 69 Suppl 2:S176-81. PMC: 4505917. DOI: 10.1097/QAI.0000000000000659. View

Kariisa M, Scholl L, Wilson N, Seth P, Hoots B . Drug Overdose Deaths Involving Cocaine and Psychostimulants with Abuse Potential - United States, 2003-2017. MMWR Morb Mortal Wkly Rep. 2019; 68(17):388-395. PMC: 6541315. DOI: 10.15585/mmwr.mm6817a3. View

Dluzen D, Liu B . Gender differences in methamphetamine use and responses: a review. Gend Med. 2008; 5(1):24-35. DOI: 10.1016/s1550-8579(08)80005-8. View

Bach P, Milloy M, Nguyen P, Koehn J, Guillemi S, Kerr T . Gender differences in access to methadone maintenance therapy in a Canadian setting. Drug Alcohol Rev. 2015; 34(5):503-507. PMC: 4573369. DOI: 10.1111/dar.12251. View

Vearrier D, Greenberg M, Miller S, Okaneku J, Haggerty D . Methamphetamine: history, pathophysiology, adverse health effects, current trends, and hazards associated with the clandestine manufacture of methamphetamine. Dis Mon. 2012; 58(2):38-89. DOI: 10.1016/j.disamonth.2011.09.004. View

Darke S, Marel C, Mills K, Ross J, Slade T, Burns L . Patterns and correlates of non-fatal heroin overdose at 11-year follow-up: findings from the Australian Treatment Outcome Study. Drug Alcohol Depend. 2014; 144:148-52. DOI: 10.1016/j.drugalcdep.2014.09.001. View

10.

Strathdee S, Patrick D, Currie S, Cornelisse P, Rekart M, Montaner J . Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS. 1997; 11(8):F59-65. DOI: 10.1097/00002030-199708000-00001. View

11.

Marshall B, Fairbairn N, Li K, Wood E, Kerr T . Physical violence among a prospective cohort of injection drug users: a gender-focused approach. Drug Alcohol Depend. 2008; 97(3):237-46. PMC: 2570226. DOI: 10.1016/j.drugalcdep.2008.03.028. View

12.

Brecht M, Greenwell L, von Mayrhauser C, Anglin M . Two-year outcomes of treatment for methamphetamine use. J Psychoactive Drugs. 2007; Suppl 3:415-26. DOI: 10.1080/02791072.2006.10400605. View

13.

Glick S, Burt R, Kummer K, Tinsley J, Banta-Green C, Golden M . Increasing methamphetamine injection among non-MSM who inject drugs in King County, Washington. Drug Alcohol Depend. 2017; 182:86-92. PMC: 6457905. DOI: 10.1016/j.drugalcdep.2017.10.011. View

14.

Marshall B, Shoveller J, Wood E, Patterson T, Kerr T . Difficulty accessing syringes mediates the relationship between methamphetamine use and syringe sharing among young injection drug users. AIDS Behav. 2011; 15(7):1546-53. PMC: 3180618. DOI: 10.1007/s10461-010-9876-8. View

15.

Al-Tayyib A, Koester S, Langegger S, Raville L . Heroin and Methamphetamine Injection: An Emerging Drug Use Pattern. Subst Use Misuse. 2017; 52(8):1051-1058. PMC: 5642954. DOI: 10.1080/10826084.2016.1271432. View

16.

Collins A, Bardwell G, McNeil R, Boyd J . Gender and the overdose crisis in North America: Moving past gender-neutral approaches in the public health response. Int J Drug Policy. 2019; 69:43-45. PMC: 10894462. DOI: 10.1016/j.drugpo.2019.05.002. View

17.

Rusch M, Lozada R, Pollini R, Vera A, Patterson T, Case P . Polydrug use among IDUs in Tijuana, Mexico: correlates of methamphetamine use and route of administration by gender. J Urban Health. 2009; 86(5):760-75. PMC: 2729865. DOI: 10.1007/s11524-009-9377-0. View

18.

Meacham M, Strathdee S, Rangel G, Armenta R, Gaines T, Garfein R . Prevalence and Correlates of Heroin-Methamphetamine Co-Injection Among Persons Who Inject Drugs in San Diego, California, and Tijuana, Baja California, Mexico. J Stud Alcohol Drugs. 2016; 77(5):774-81. PMC: 5015469. DOI: 10.15288/jsad.2016.77.774. View

19.

Courtney K, Ray L . Methamphetamine: an update on epidemiology, pharmacology, clinical phenomenology, and treatment literature. Drug Alcohol Depend. 2014; 143:11-21. PMC: 4164186. DOI: 10.1016/j.drugalcdep.2014.08.003. View

20.

Reback C, Fletcher J . HIV prevalence, substance use, and sexual risk behaviors among transgender women recruited through outreach. AIDS Behav. 2013; 18(7):1359-67. PMC: 4209944. DOI: 10.1007/s10461-013-0657-z. View